These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 8715799)

  • 21. Conversion from Sandimmune to Neoral in stable heart transplant recipients.
    Pethig K; Ruhparwar A; Korn A; Christians U; Wahlers T
    Transplant Proc; 1996 Aug; 28(4):2287-9. PubMed ID: 8769228
    [No Abstract]   [Full Text] [Related]  

  • 22. Conventional versus Neoral cyclosporine in renal transplantation.
    Rovelli E; Bucci A; Maldifassi P; Belfiore A; D'Amico G
    Transplant Proc; 1998 Aug; 30(5):1764-5. PubMed ID: 9723272
    [No Abstract]   [Full Text] [Related]  

  • 23. Successful reconversion from tacrolimus to cyclosporine A Neoral in pediatric liver recipients.
    Melter M; Rodeck B; Kardorff R; Hoyer PF; Maibücher A; Brodehl J
    Transplant Proc; 1996 Aug; 28(4):2276-8. PubMed ID: 8769224
    [No Abstract]   [Full Text] [Related]  

  • 24. Conversion from Sandimmune to Neoral in renal transplant recipients: two-year experience.
    Wilczek HE; Akesson P; Warholm C
    Transplant Proc; 1998 Aug; 30(5):1753-5. PubMed ID: 9723267
    [No Abstract]   [Full Text] [Related]  

  • 25. Case study: conversion of a liver transplant patient from cyclosporine Sandimmune to Neoral.
    Levy GA
    Transplant Proc; 1996 Aug; 28(4):2252-3. PubMed ID: 8769216
    [No Abstract]   [Full Text] [Related]  

  • 26. Experience with conversion from Sandimmun to Neoral cyclosporine and the correlation of C2 levels with renal function.
    Konstadinidou I; Boletis JN
    Transplant Proc; 2004 Mar; 36(2 Suppl):163S-166S. PubMed ID: 15041329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changing stable heart transplant recipients from Sandimmune to Neoral.
    Dalrymple-Hay M; Meara M; Reynolds L; Backhouse L; Wright D; Holt D; Johnston A; Madden B; Murday A
    Transplant Proc; 1996 Aug; 28(4):2285-6. PubMed ID: 8769227
    [No Abstract]   [Full Text] [Related]  

  • 28. Conversion from Sandimmune to Neoral in stable renal transplant recipients. Sandoz Study Group OLN-353.
    Pescovitz MD
    Transplant Proc; 1996 Aug; 28(4):2196-8. PubMed ID: 8769198
    [No Abstract]   [Full Text] [Related]  

  • 29. Estimation of mean relative bioavailability of cyclosporine Sandimmune and Neoral using NONMEM in renal transplant recipients.
    Lee KL; Lee KT; Chung HM; Lin YP
    Transplant Proc; 1998 Nov; 30(7):3526-9. PubMed ID: 9838545
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparison of generic cyclosporine microemulsion versus neoral in de novo renal transplant recipients managed by 2-hour postdose monitoring.
    Sharma A; Shekhar C; Heer M; Minz M
    Transplant Proc; 2006 Sep; 38(7):2051-3. PubMed ID: 16979996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Converting renal transplant patients maintained on Sandimmune to a new microemulsion formulation, Sandimmune Neoral.
    Chu SH; Pang ST; Chiang YJ; Chuang CK; Chen HW; Chen CS; Chou CC; Huang CC
    Transplant Proc; 1998 Nov; 30(7):3521-3. PubMed ID: 9838543
    [No Abstract]   [Full Text] [Related]  

  • 32. Conversion from once-daily Sandimmune cyclosporine to once-daily Neoral in renal transplant patients.
    Arvind C; Vathsala A; Woo KT
    Transplant Proc; 2000 Nov; 32(7):1681-2. PubMed ID: 11119890
    [No Abstract]   [Full Text] [Related]  

  • 33. Mass conversion from Sandimmun to Sandimmun Neoral: 1 1/2-year experience.
    Huraib S; al Khudair W; Selim H; Iqbal A; Quadri K; Abu Romeh S; Chaballout A
    Transplant Proc; 1997 Nov; 29(7):2980-2. PubMed ID: 9365637
    [No Abstract]   [Full Text] [Related]  

  • 34. The impact of cyclosporine on the development of immunosuppressive therapy: perspective from a transplant nephrologist involved with the development of C2.
    Cole E; Deshpande R
    Transplant Proc; 2004 Mar; 36(2 Suppl):408S-413S. PubMed ID: 15041376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimizing Neoral therapeutic drug monitoring with cyclosporine trough (C(0)) and C(2) concentrations in stable renal allograft recipients.
    Einecke G; Mai I; Diekmann F; Fritsche L; Boehler T; Neumayer HH; Budde K
    Transplant Proc; 2001; 33(7-8):3102-3. PubMed ID: 11750333
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacoeconomics of Neoral, a new formulation of cyclosporine, in renal transplantation.
    Abella I
    Transplant Proc; 1996 Dec; 28(6):3131-4. PubMed ID: 8962213
    [No Abstract]   [Full Text] [Related]  

  • 37. Estimated area-under-the-curve monitoring of Neoral in a stable pediatric renal transplant population: one-year experience.
    Lemire J; Capparelli EV; MacDonald D; Benador N; Reznik VM; Mendoza SA; Griswold WR
    Transplant Proc; 1998 Aug; 30(5):1983-4. PubMed ID: 9723361
    [No Abstract]   [Full Text] [Related]  

  • 38. Conversion from Sandimmune to Neoral in patients with stable renal allograft function: UHKL experience.
    Goh BL; Jalil R; Koh SN; Chua CT; Tan SY
    Transplant Proc; 1998 Nov; 30(7):3535-6. PubMed ID: 9838548
    [No Abstract]   [Full Text] [Related]  

  • 39. Modification of the pharmacokinetics of cyclosporine A and metabolites by the concomitant use of Neoral and diltiazem or ketoconazol in stable adult kidney transplants.
    Foradori A; Mezzano S; Videla C; Pefaur J; Elberg A
    Transplant Proc; 1998 Aug; 30(5):1685-7. PubMed ID: 9723244
    [No Abstract]   [Full Text] [Related]  

  • 40. Therapeutic monitoring of cyclosporine in kidney transplantation: the Halifax experience.
    Singh D; Kiberd B; Belitsky P; Fraser A; Balbontin F; Lawen J
    Transplant Proc; 2004 Mar; 36(2 Suppl):414S-419S. PubMed ID: 15041377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.